Drugs / HDM2012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07100249 | Aug 2025 → Oct 2027 expected | cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM2012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07100249 ↗ |
| Route | Intravenous | “HDM2012 will be administered via IV infusion.” NCT07100249 ↗ |